Core Insights - In the first four months of this year, 368 out of 650 comparable QDII funds saw an increase in net value, representing approximately 56.6% of the total funds [1] - The top-performing funds were Huatai-PineBridge Hong Kong Advantage Selection Mixed A and C, with returns of 59.43% and 59.19% respectively [1] - The fund manager Zhang Wei believes that the pharmaceutical industry will continue to show good anti-cyclical and technological attributes over the next 2 to 3 years, focusing on innovative drugs and high-barrier leading companies in medical equipment [1] Fund Performance - The second tier of QDII funds includes nine funds with returns between 30% and 35%, such as ICBC New Economy Mixed RMB and USD, and E Fund Gold Theme funds [2] - Specifically, ICBC New Economy Mixed RMB and USD achieved returns of 34.25% and 34.01% respectively, maintaining a high position in innovative drug investments [2] - The top ten holdings for these funds include companies like Kelun Pharmaceutical and Innovent Biologics [2] Gold-Themed Funds - E Fund Gold Theme funds benefited from the rise in gold and gold stocks, with returns of 31.21% to 30.71% [3] - These funds shifted their holdings from gold stocks to gold itself as of March, focusing on gold as the primary asset [3] Declining Funds - A total of 49 QDII funds experienced declines of over 10%, with the largest drop being 16.12%, primarily in oil and gas-related sectors [3] Performance Rankings - The performance rankings for QDII funds show that Huatai-PineBridge Hong Kong Advantage Selection Mixed A and C lead the pack, while several oil and gas-focused funds are at the bottom of the list [4][5]

Core Insights - In April 2025, out of 668 comparable QDII funds, 346 funds saw an increase in net value, representing over 50% of the total [1] - Only 2 QDII funds had a growth rate exceeding 10%, with 汇添富香港优势精选混合C and 汇添富香港优势精选混合A achieving returns of 14.70% and 14.65% respectively [2] - A total of 38 QDII funds recorded growth between 5% and 10% [3] - 23 QDII funds experienced a decline of over 10%, primarily in the oil and gas sector, with the largest drop being 16.98% [5] Fund Performance - 汇添富香港优势精选混合A and C have year-to-date returns of 59.43% and 59.19%, respectively, since their inception returns are 8.61% and 2.61% [2] - 富国蓝筹精选股票人民币 fund achieved an April return of 8.20% and a year-to-date return of 28.31%, with an inception return of 146.39% [3] - The top holdings for 汇添富香港优势精选混合 funds include companies like 荣昌生物 and 科伦博泰生 [2] Fund Management - The fund manager for 汇添富香港优势精选混合 funds is 张韡, who has extensive experience in the pharmaceutical sector [2] - 富国蓝筹精选股票人民币 is managed by 张峰 and 宁君, both of whom have significant backgrounds in investment banking and fund management [4] Market Trends - The QDII fund market shows a strong performance in the pharmaceutical and technology sectors, with a focus on innovative drugs and high-barrier medical equipment [2][3] - The decline in certain funds is attributed to volatility in the oil and gas market, indicating sector-specific risks [5]